Raeburn B. Forbes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raeburn B. Forbes has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Robert J Swingler
Neurology Section, Department of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, UK
5 shared publicationsRobert J. Swingler
Department of Neurology, Royal Victoria Hospital, Belfast,Northern Ireland BT12 6BA, UK
4 shared publicationsShuna Colville
Department of Neurology, Royal Victoria Hospital, Belfast,Northern Ireland BT12 6BA, UK
3 shared publicationsG V McDonnell
Department of Neurology, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, Northern Ireland
2 shared publicationsJ. Parratt
Ninewells Hospital and Medical School
2 shared publications- Mark Owen McCarron
Neurology, Altnagelvin Hospital, Derry, UK
2 shared publications
Latest Publications
- 15 July 2020
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 60 (8) , 1542-1557
Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta‐analysis
Background: CGRP Antibodies are high‐cost newly licensed migraine preventatives. Objective: To calculate the overall reduction in monthly migraine days and the proportion contextual effect (PCE) using meta‐analysis. The PCE is the ratio between the reduction in Monthly Migraine Days in the placebo group and the reduction in Monthly Migraine Days in the CGRP‐Ab group after 3 months of treatment. Methods: Meta‐analysis of randomized double‐blind placebo‐controlled trials of anti‐CGRP antibodies in people with episodic migraine (EM) or chronic migraine (CM) in persons aged 18 or over. Non‐randomized trials and trials in persons under 18 years excluded. Search of National Clinical Trials Register 2000‐2019, MEDLINE to September 2019, Hand search of major headache conference abstract books 2012‐2019. Two investigators used standard proforma to reach consensus. Trial quality assessed using Cochrane Collaboration risk of bias tool. PRISMA guidelines followed. Results: 21 completed trials with 13367 participants (8075 EM, 5292 CM). Compared to placebo, pooled reduction in MMD was 1.50 days in 15 EM trials (95%CI 1.16, 1.84; I 2 = 69%, P hetereogeneity < .001) and 2.24 days in 7 CM trials (95%CI 1.82, 2.65, I 2 = 15%, P hetereogeneity = .320). In EM trials, pooled PCE was 0.66 (95%CI 0.59,0.75; I 2 = 64%, P hetereogeneity = .001). In CM trials the PCE was .68 (95%CI 0.61, 0.75; I 2 = 20%, P hetereogeneity = .280). Industry funded every study, but risk of bias was low. Conclusions: CGRPAbs are effective but sixty‐six percent of the benefit is from contextual effects, including placebo effect. Contextual effects merit further scrutiny as a means of improving migraine headache.
- 15 July 2020
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 60 (8) , 1542-1557
Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta‐analysis
Background: CGRP Antibodies are high‐cost newly licensed migraine preventatives. Objective: To calculate the overall reduction in monthly migraine days and the proportion contextual effect (PCE) using meta‐analysis. The PCE is the ratio between the reduction in Monthly Migraine Days in the placebo group and the reduction in Monthly Migraine Days in the CGRP‐Ab group after 3 months of treatment. Methods: Meta‐analysis of randomized double‐blind placebo‐controlled trials of anti‐CGRP antibodies in people with episodic migraine (EM) or chronic migraine (CM) in persons aged 18 or over. Non‐randomized trials and trials in persons under 18 years excluded. Search of National Clinical Trials Register 2000‐2019, MEDLINE to September 2019, Hand search of major headache conference abstract books 2012‐2019. Two investigators used standard proforma to reach consensus. Trial quality assessed using Cochrane Collaboration risk of bias tool. PRISMA guidelines followed. Results: 21 completed trials with 13367 participants (8075 EM, 5292 CM). Compared to placebo, pooled reduction in MMD was 1.50 days in 15 EM trials (95%CI 1.16, 1.84; I 2 = 69%, P hetereogeneity < .001) and 2.24 days in 7 CM trials (95%CI 1.82, 2.65, I 2 = 15%, P hetereogeneity = .320). In EM trials, pooled PCE was 0.66 (95%CI 0.59,0.75; I 2 = 64%, P hetereogeneity = .001). In CM trials the PCE was .68 (95%CI 0.61, 0.75; I 2 = 20%, P hetereogeneity = .280). Industry funded every study, but risk of bias was low. Conclusions: CGRPAbs are effective but sixty‐six percent of the benefit is from contextual effects, including placebo effect. Contextual effects merit further scrutiny as a means of improving migraine headache.
- Open Access
- 14 August 2014
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 15 (1) , 49
A systematic review of causes of sudden and severe headache (Thunderclap Headache): should lists be evidence based?
Background: There are many potential causes of sudden and severe headache (thunderclap headache), the most important of which is aneurysmal subarachnoid haemorrhage. Published academic reviews report a wide range of causes. We sought to create a definitive list of causes, other than aneurysmal subarachnoid haemorrhage, using a systematic review.Methods: Systematic Review of EMBASE and MEDLINE databases using pre-defined search criteria up to September 2009. We extracted data from any original research paper or case report describing a case of someone presenting with a sudden and severe headache, and summarized the published causes.Results: Our search identified over 21,000 titles, of which 1224 articles were scrutinized in full. 213 articles described 2345 people with sudden and severe headache, and we identified 6 English language academic review articles. A total of 119 causes were identified, of which 46 (38%) were not mentioned in published academic review articles. Using capture-recapture analysis, we estimate that our search was 98% complete. There is only one population-based estimate of the incidence of sudden and severe headache at 43 cases per 100,000. In cohort studies, the most common causes identified were primary headaches or headaches of uncertain cause. Vasoconstriction syndromes are commonly mentioned in case reports or case series. The most common cause not mentioned in academic reviews was pneumocephalus. 70 non-English language articles were identified but these did not contain additional causes.Conclusions: There are over 100 different published causes of sudden and severe headache, other than aneurysmal subarachnoid haemorrhage. We have now made a definitive list of causes for future reference which we intend to maintain. There is a need for an up to date population based description of cause of sudden and severe headache as the modern epidemiology of thunderclap headache may require updating in the light of research on cerebral vasoconstriction syndromes.
- 14 August 2014
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 15 (1) , 49
Open AccessA systematic review of causes of sudden and severe headache (Thunderclap Headache): should lists be evidence based?
Background: There are many potential causes of sudden and severe headache (thunderclap headache), the most important of which is aneurysmal subarachnoid haemorrhage. Published academic reviews report a wide range of causes. We sought to create a definitive list of causes, other than aneurysmal subarachnoid haemorrhage, using a systematic review.Methods: Systematic Review of EMBASE and MEDLINE databases using pre-defined search criteria up to September 2009. We extracted data from any original research paper or case report describing a case of someone presenting with a sudden and severe headache, and summarized the published causes.Results: Our search identified over 21,000 titles, of which 1224 articles were scrutinized in full. 213 articles described 2345 people with sudden and severe headache, and we identified 6 English language academic review articles. A total of 119 causes were identified, of which 46 (38%) were not mentioned in published academic review articles. Using capture-recapture analysis, we estimate that our search was 98% complete. There is only one population-based estimate of the incidence of sudden and severe headache at 43 cases per 100,000. In cohort studies, the most common causes identified were primary headaches or headaches of uncertain cause. Vasoconstriction syndromes are commonly mentioned in case reports or case series. The most common cause not mentioned in academic reviews was pneumocephalus. 70 non-English language articles were identified but these did not contain additional causes.Conclusions: There are over 100 different published causes of sudden and severe headache, other than aneurysmal subarachnoid haemorrhage. We have now made a definitive list of causes for future reference which we intend to maintain. There is a need for an up to date population based description of cause of sudden and severe headache as the modern epidemiology of thunderclap headache may require updating in the light of research on cerebral vasoconstriction syndromes.
- 1 May 2014
- Vol. 83 (2) , 93-102
Diagnostic Lumbar Puncture
Diagnostic Lumbar Puncture is one of the most commonly performed invasive tests in clinical medicine. Evaluation of an acute headache and investigation of inflammatory or infectious disease of the nervous system are the most common indications. Serious complications are rare, and correct technique will minimise diagnostic error and maximise patient comfort. We review the technique of diagnostic Lumbar Puncture including anatomy, needle selection, needle insertion, measurement of opening pressure, Cerebrospinal Fluid (CSF) specimen handling and after care. We also make some quality improvement suggestions for those designing services incorporating diagnostic Lumbar Puncture.
- 1 May 2014
- Vol. 83 (2) , 93-102
Diagnostic Lumbar Puncture
Diagnostic Lumbar Puncture is one of the most commonly performed invasive tests in clinical medicine. Evaluation of an acute headache and investigation of inflammatory or infectious disease of the nervous system are the most common indications. Serious complications are rare, and correct technique will minimise diagnostic error and maximise patient comfort. We review the technique of diagnostic Lumbar Puncture including anatomy, needle selection, needle insertion, measurement of opening pressure, Cerebrospinal Fluid (CSF) specimen handling and after care. We also make some quality improvement suggestions for those designing services incorporating diagnostic Lumbar Puncture.
- 1 January 2014
- Vol. 83 (1) , 3-9
Acute Headache
- 16 December 2008
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 80 (1) , 84-87
Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register
Background: The Scottish Motor Neurone Disease Register is a population based register of amyotrophic lateral sclerosis/motor neurone disease (ALS/MND) in Scotland, with high case ascertainment levels. Objective: To investigate the cause of death by autopsy and assess grading criteria in a cohort of cases of ALS from the Scottish MND Register. Methods: The records of 44 patients undergoing autopsy were reviewed to determine the cause of death, clinical assessment (El Escorial and modified World Federation of Neurology criteria) during life and neuropathological autopsy findings. Results: In a cohort of 44 cases undergoing autopsy between 1989 and 1998, the cause of death could be directly or indirectly (bronchopneumonia, aspiration/pneumonia and respiratory failure) attributed to MND in 32/44 (73%) cases. The clinical diagnosis of MND was confirmed at autopsy in 44/44 (100%) cases, 3/44 (7%) cases showed coexistent neurodegenerative disease and 5/44 (11%) were familial MND cases. Conclusions: Within our cohort, MND contributes to death in the majority of cases and there is excellent clinicopathological correlation, irrespective of the clinical grading criteria used. However, the autopsy rate is low (4%) and further larger studies are required to identify heterogeneity within the disease.
- 16 December 2008
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 80 (1) , 84-87
Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register
Background: The Scottish Motor Neurone Disease Register is a population based register of amyotrophic lateral sclerosis/motor neurone disease (ALS/MND) in Scotland, with high case ascertainment levels. Objective: To investigate the cause of death by autopsy and assess grading criteria in a cohort of cases of ALS from the Scottish MND Register. Methods: The records of 44 patients undergoing autopsy were reviewed to determine the cause of death, clinical assessment (El Escorial and modified World Federation of Neurology criteria) during life and neuropathological autopsy findings. Results: In a cohort of 44 cases undergoing autopsy between 1989 and 1998, the cause of death could be directly or indirectly (bronchopneumonia, aspiration/pneumonia and respiratory failure) attributed to MND in 32/44 (73%) cases. The clinical diagnosis of MND was confirmed at autopsy in 44/44 (100%) cases, 3/44 (7%) cases showed coexistent neurodegenerative disease and 5/44 (11%) were familial MND cases. Conclusions: Within our cohort, MND contributes to death in the majority of cases and there is excellent clinicopathological correlation, irrespective of the clinical grading criteria used. However, the autopsy rate is low (4%) and further larger studies are required to identify heterogeneity within the disease.
- 1 June 2008
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 17 (4) , 387-388
Cost-utility of vagus nerve stimulation (VNS) therapy for medically refractory epilepsy—An update
- 1 June 2008
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 17 (4) , 387-388
Cost-utility of vagus nerve stimulation (VNS) therapy for medically refractory epilepsy—An update
- 10 April 2007
- Published by Springer Nature in Journal of Neurology
- Vol. 254 (7) , 866-869
The incidence of motor nueron disease in Scotland
- 10 April 2007
- Published by Springer Nature in Journal of Neurology
- Vol. 254 (7) , 866-869
The incidence of motor nueron disease in Scotland
- 1 August 2006
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 12 (4) , 507-510
A systematic review of oral methotrexate for multiple sclerosis
Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.
- 1 August 2006
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 12 (4) , 507-510
A systematic review of oral methotrexate for multiple sclerosis
Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.
Review of publication bias in studies on publication bias: Systematic review is needed
Footnotes Competing interests None declared.
Review of publication bias in studies on publication bias: Systematic review is needed
Footnotes Competing interests None declared.
- 1 August 2005
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 11 (4) , 403-408
Multiple sclerosis in Tayside, Scotland: detection of clusters using a spatial scan statistic
Debate continues over the relative importance of genetic factors over infectious agents in the aetiology of multiple sclerosis (MS). Detection of clusters of MS in space and time in the Tayside region of Scotland, UK would provide valuable evidence for the movement of infectious agents into a genetically susceptible population. A spatial scan statistic was used to detect, locate and provide a robust statistical test of any clusters found, without prior knowledge of their location or size. This was applied to a population-based MS register for the Tayside region of Scotland from 1970 to 1997, allowing for age at symptom onset, gender, population density and social deprivation. There were a total of 772 cases during the study period; an annual incidence of 7.2 per 100 000. The mean age of symptom onset was 35.7 (SD=10.5) and 73.8% of cases were women. There was a general increase in cases over time probably reflecting gradually better detection and diagnosis. There was a peak around the mid-1990s and some evidence of periodicity. There was a highly significant temporal cluster between 1982 and 1995 (p=0.002) for the whole region. Additionally, a significant spatial cluster for the time period 1993-1995 was found centred in the rural area south-west of Perth (p=0.016). Significant temporal and spatial-temporal clusters are consistent with exogenous factors contributing to the distribution of MS in Tayside, Scotland.
- 1 August 2005
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 11 (4) , 403-408
Multiple sclerosis in Tayside, Scotland: detection of clusters using a spatial scan statistic
Debate continues over the relative importance of genetic factors over infectious agents in the aetiology of multiple sclerosis (MS). Detection of clusters of MS in space and time in the Tayside region of Scotland, UK would provide valuable evidence for the movement of infectious agents into a genetically susceptible population. A spatial scan statistic was used to detect, locate and provide a robust statistical test of any clusters found, without prior knowledge of their location or size. This was applied to a population-based MS register for the Tayside region of Scotland from 1970 to 1997, allowing for age at symptom onset, gender, population density and social deprivation. There were a total of 772 cases during the study period; an annual incidence of 7.2 per 100 000. The mean age of symptom onset was 35.7 (SD=10.5) and 73.8% of cases were women. There was a general increase in cases over time probably reflecting gradually better detection and diagnosis. There was a peak around the mid-1990s and some evidence of periodicity. There was a highly significant temporal cluster between 1982 and 1995 (p=0.002) for the whole region. Additionally, a significant spatial cluster for the time period 1993-1995 was found centred in the rural area south-west of Perth (p=0.016). Significant temporal and spatial-temporal clusters are consistent with exogenous factors contributing to the distribution of MS in Tayside, Scotland.